Citations

Clear

14 citation(s) found for "Shah, Neil D".

Transplantation of older DCD livers in the machine perfusion era: a U.S. cohort study
Ziogas, Ioannis A., Moris, Dimitrios, Theocharopoulos, Charalampos , Yoeli, Dor, Adams, Megan A., Barbas, Andrew S. , Montenovo, Martin I. , Chen, M G, Kapoor, Sorabh , Calderon, Esteban , Moon, Andrew M., Deutch-Link, Sasha, Shroff, Hersh , Barritt, A. Sidney, Mathur, Amit K., Nydam, Trevor, Desai, Chirag S., Schegel, Andrea, Chen, Melissa, Shah, Neil D, Giorgakis, Emmanouil , Ziogas, Ioannis A. , Varvoglis, Dimitrios N. , Yoeli, Dor , Adams, Megan A. , Moon, Andrew M , Deutsch‐Link, Sasha , Shah, Neil , Fix, Oren K. , Barritt, A. Sidney, Nydam, Trevor L. , Desai, Chirag S., Martins, Paulo N.

Mayo Clinic

Transplant International | May 29, 2026 | Volume: 39 | Issue: No issue available | Pages: No page available

10.3389/ti.2026.16689 | PMID 42294094 Get It

Donation after circulatory death (DCD) livers increasingly use machine perfusion (MP). This study evaluates MP’s impact on older DCD livers based on data from the United Network for Data Sharing, covering all first adult DCD liver transplants (2016–2025). The cohort, divided into pre-MP and MP eras (separated by the FDA approval of the first normothermic MP platform in 2021), showed accelerated growth in DCD liver transplants during the MP era. Donors ≥60 rose 7.8-fold, including donors ≥70 (a USA first). By 2025, DCD livers accounted for 43.2%, with 61.35% from donors ≥50. Normothermic regional perfusion (NRP) (3.0%–21.7%), NMP (2.3%–35.6%), and sequential NRP-NMP (0.1%–19.2%) increased significantly (p < 0.001). The MP era was associated with a decrease in median waitlist time from 112 to 62 days (p < 0.001). Early graft survival was similar across ages. For ages 50–59, 1- and 3-year survivals were 87.9%/78.4% pre-MP and 90.1%/78.8% in the MP era. For 60–69, survival was 85.0%/80.6% pre-MP and 90.0%/71.3% in the MP era. DCD LTs for ≥70 were limited to the MP era with 87.8% 1-year survival. Multivariable Cox regression showed that static cold storage (HR = 1.19), donor age 50–69 versus 18–49, and recipient age (HR = 1.04) increased the risk of graft loss after adjustment. MP is associated with an increased number of older DCD liver transplants and acceptable early graft survival.
Validation of MELD 3.0 in 2 centers from different continents
Duong, Nikki, Huynh, Daniel J. , Kim, W. Ray, Shah, Neil , Biggins, Scott W. , Kwong, Allison, Kwong, Allison J. , Duong, Nikki , Kwong, Allison , Nikzad, Newsha , Shah, Neil

Mayo Clinic

Hepatology Communications | May 22, 2026 | Volume: 10 | Issue: 6 | Pages: No page available

10.1097/hc9.0000000000000958 | PMID 42172502 Get It

Deriving wisdom from data: The value and continued rationale for structured data in the era of artificial intelligence–driven oncology care
Emamekhoo, Hamid, Riaz, Irbaz, Martin, Daniel B., Gabriel, Peter E. , Bruckner, Lauren B. , Arafat, Waddah, Fu, Penelope, Liebovitz, David , Stillman, Robert C. , Stapp, Robert T, Perkins, Randa M., Sugalski, Jessica , Heinrichs, Tricia , Tevaarwerk, Amye J., Gabriel, Peter , Emamekhoo, Hamid , Emamekhoo, Hamid , Stillman, Robert C , Heinrichs, Tricia , Tevaarwerk, Amye J , Shah, Neil J , Arafat, Waddah , Freimuth, Robert R. , Stapp, Robert , Perkins, Randa, Tevaarwerk, Amyé

Mayo Clinic

Cancer | February 17, 2026 | Volume: 132 | Issue: 4 | Pages: No page available

10.1002/cncr.70307 | PMID 41701629 Get It

Abstract The adoption of electronic health records (EHRs) has transformed health care, improving efficiency and chart accessibility. However, the widespread reliance on unstructured data entry and the lack of standardized documentation frameworks have resulted in significant data fragmentation across health care systems. The prevalence of unstructured data in EHRs limits their potential for clinical decision support, trial matching, real‐world evidence (RWE) generation, and quality measurement. Data fragmentation in health care triggers a cascade of challenges that ultimately compromise patient care. Clinicians face an excessive documentation burden and struggle to locate critical information buried in unstructured notes. Researchers encounter difficulties in extracting reliable clinical data. EHR vendors grapple with standardizing unstructured information for interoperability, and payers are unable to process unstructured clinical data efficiently to support value‐based care models. These challenges are particularly acute in oncology, where complex clinical elements like cancer staging, disease status, and treatment changes require precise, structured documentation. Emerging artificial intelligence (AI) technologies, such as large language models (LLMs) and ambient listening, offer a path to automate structured data generation while reducing the workload on providers. Here, the authors propose LLM‐based workflows that balance automation with clinician verification, streamlining data entry without compromising accuracy. Realizing these benefits requires coordinated efforts among clinicians, researchers, EHR vendors, payers, and policymakers to align regulatory frameworks with AI‐driven innovations. This article outlines a strategy to enhance structured data capture within EHRs, ultimately improving patient care, research, and health care efficiency.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shah, Neil P. , Bhatia, Ravi , Altman, Jessica K. , Amaya, Maria L. , Begna, Kebede H. , Berman, Ellin , Clements, Joan , Collins, Robert H. , Curtin, Peter , Drazer, Michael W. , Maness, Lori J., Metheny, Leland , Moore, Joseph O., Oehler, Vivian G. , Pratz, Keith W. , Pusic, Iskra , Rose, Michal G., Shomali, William , Styler, Michael , Tanaka, Tiffany , Tantravahi, Srinivas K. , Thompson, James E. , Tsai, Steven , Vaughn, Jennifer E. , Welborn, Jeanna, Yang, David T. , Sundar, Hema, Gregory, Kristina M., Drazer, Michael , Bhatia, Ravi , Chan, Onyee , DeAngelo, Daniel J. , Mohan, Sanjay , Smith, B. Douglas , Talpaz, Moshe , Amaya, Maria

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 23, 2024 | Volume: 22 | Issue: 1 | Pages: 43-69

10.6004/jnccn.2024.0007 | PMID 38394770 Get It

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase–CML. The primary goal of TKI therapy in patients with chronic phase–CML is to prevent disease progression to accelerated phase–CML or blast phase–CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase–CML.
Acupuncture in Sports Medicine
Pujalte, George , Malone, Michael A. , Mandavalli, Akhil , Phrathep, Davong D , Shah, N. , Perlman, Adam , Pujalte, George G A , Malone, Michael , Phrathep, Davong David , Shah, Neil P , Perlman, Adam

Mayo Clinic

Journal of Acupuncture and Meridian Studies | December 20, 2023 | Volume: 16 | Issue: 6 | Pages: 239-247

10.51507/j.jams.2023.16.6.239 | PMID 38115589 Get It

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice
Thompson, James E. , Gao, Yan , Visotcky, Alexis, Mauro, Michael J. , Giever, Emily, Baim, Arielle , Akinola, Idayat , Cortes, Jörge E. , Shah, Neil P. , Pinilla‐Ibarz, Javier , Yang, Jay , Ritchie, Ellen K. , Rein, Lindsay , Tantravahi, Srinivas K. , Deininger, Michael W. , Cortes, Jorge , Visotcky, Alexis, Flynn, Kathryn E. , Larson, Richard A. , Jamy, Omer , Hunter, Anthony M. , Kota, Vamsi , Druker, Brian J , Smith, B. Douglas , Badar, Talha , Atallah, Ehab

Mayo Clinic

Blood | December 2, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 7420-7420

10.1182/blood-2023-179963 Get It

Background: First-line therapies for chronic-phase (CP) CML include the tyrosine kinase inhibitors(TKIs) dasatinib, nilotinib, bosutinib or imatinib, while ponatinib and asciminib are indicated only in later lines. There are typically high response rates to first-line therapy in CP-CML, with responses to second- and third-line therapy lower and highly dependent on the specific TKI. Our goal in this study is to evaluate the role of ponatinib in the treatment of patients with CML using data from routine clinical practice. Study design and methods: Data will come from the H. Jean Khoury Cure CML Consortium (HJKC3) CML registry, a North American multi-site research database. Participating sites include the HJKC3 members (curecml.org). Patient inclusion criteria include a diagnosis CML in chronic phase, receiving second line therapy after initial therapy with a second generation TKI (dasatinib, nilotinib, or bosutinib) or receiving third or later line TKI therapy for CML. Participating patients provide consent to collect their data both retrospectively and prospectively for 1 year. Clinical data, including toxicities and complications of TKI therapy, are abstracted from the electronic health record. Participating patients are invited to complete a questionnaire to assess health-related quality of life. Data are managed using REDCap, a secure web application. Study Objectives: The primary objective is to compare the outcome of patients treated with ponatinib vs. other TKIs as second or later line therapy. Secondary objectives are to evaluate patient-reported outcomes (PRO) for CML treated with second or later line therapy and to determine if there are any patient or disease characteristics that can predict outcomes. Statistical plan for clinical outcomes: Descriptive statistics will be used to compare baseline demographic characteristics. Categorical variables will be compared using the Chi-square test. Continuous variables will be compared using ANOVA. Overall survival will be calculated from the time of diagnosis to death from any cause and patients will be censored if they were alive at the last follow-up. Survival probabilities will be computed using the Kaplan-Meier method and compared with the log-ranktest. Cox regression analyses will be used to determine significant factors that influence survival, and hazard ratios with 95% confidence intervals will be presented. Event free survival (EFS) and transformation free survival (TFS) will be calculated for patients. For EFS, loss of complete hematologic remission, loss of major cytogenetic response, progression to accelerated or blast phase, or death from any cause at any time will be considered an event. For TFS, transformation to accelerated or blast phase while on therapy or death on study will be considered an event. Statistical plan for PRO: Different PRO domains will be analyzed separately (for example, depression separate from fatigue, etc.). Descriptive statistics for each PRO measure will be reported and compared to previously published studies. Differences by treatment type will be evaluated.
HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice
Mauro, Michael J. , Thompson, James E. , Gao, Yan , Visotcky, Alexis, Giever, Emily, Baim, Arielle , Akinola, Idayat , Cortes, Jörge E. , Shah, Neil P. , Pinilla‐Ibarz, Javier , Yang, Jay , Ritchie, Ellen K. , Rein, Lindsay , Tantravahi, Srinivas K. , Deininger, Michael W. , Cortes, Jorge , Atallah, Ehab , Visotcky, Alexis, Larson, Richard A. , Jamy, Omer , Druker, Brian J , Badar, Talha , Smith, B. Douglas , Flynn, Kathryn E.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 7434-7434

10.1182/blood-2023-188683 Get It

Background and significance: There are typically high response rates to first line TKI therapies in chronic phase chronic myeloid leukemia (CP-CML). However, responses in later lines (second line and beyond) are diminished and highly dependent on the specific tyrosine kinase inhibitors (TKIs) used. Asciminib received FDA approval in October 2021 for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) CML-CP who were previously treated with two or more TKIs, and in patients with Ph+ CML-CP with the T315I mutation. Our goal in this study is to evaluate the role of asciminib therapy for patients with CML beyond clinical studies, in routine clinical practice. Study Design and methods: Data for this study will be abstracted from the HJKC3 (H. Jean Khoury Cure CML Consortium) CML registry project (HJKC3-0005); the HJKC3 CML Registry is a collaborative academic multi-site registry. Patients will be consented to allow collection of both retrospective and prospective data for the HJKC3 CML Registry. The data forms and surveys will be built and managed through the Research Electronic Data Capture (REDCap), a secure web application managed by the Clinical & Translational Science Institute. Participating sites include members of the HJKC3 (curecml.org). This study will be an opportunity to evaluate asciminib usage in ‘real-world’ academic practices across the United States. This observational study will include cohorts of patients diagnosed with CP-CML previously treated with two or more tyrosine kinase inhibitors and/or receiving asciminib and/or those with a T315I mutation, not currently enrolled in a randomized controlled trial. The HJKC3 CML Registry intends to collect clinical and patient reported outcome (PRO) data. After obtaining patient consent, patients will be invited to complete PRO assessments. The study will attempt to collect PRO data regardless of disease or treatment status. PRO assessments will be primarily administered online, though study staff will offer alternatives (e.g., phone) for participants without internet access. Study subjects will be emailed a link to access a secure platform hosted by one of the study sites, Medical College of Wisconsin (MCW), using the REDCap platform. Study Objectives: The primary objective of the study is to describe characteristics of patients who were previously treated with two or more TKIs and treated with asciminib or with any other TKIs. The secondary objectives are to describe the clinical outcomes and PRO of those patients. Exploratory objectives include description of characteristics, treatment outcome and PRO for patients with T315I mutation. Statistical plan: The sample size of approximately 225 participants during the 5-year recruitment period is based on the available clinical expertise and ongoing recruitment data in the HJKC3 CML registry in lieu of statistical power analysis. We estimate that 150 patients in the HJKC3 CML registry will be treated with other TKI and 75 treated with asciminib. Among a total of 225 patients, we estimate that 75 patients with the T315I mutation will be enrolled in the registry. No formal statistical inference will be drawn to compare the outcomes between these two groups. Bayesian predictive probability (PP) will be utilized for the exploratory analysis of Major Molecular Response (MMR). Survival probabilities will be computed using the Kaplan-Meier method, and the p-values from the log-rank test will be provided. Different PRO domains of the patient's symptoms and functioning will be analyzed separately (e.g., depression separate from fatigue, separate from GI symptoms, etc.) since combining them into a summary score may dilute the effects of the individual (and not necessarily related) components and mask actual change. The main objective for the analyses of PRO data from the registry is to describe any differences by treatment type in patients treated with asciminib and other TKIs.
Knee Pain In A Recreational Runner
Jorgensen, Matthew S., Shah, Neil P. , Nadwodny, Jeffrey , Pujalte, George

Mayo Clinic

Medicine & Science in Sports & Exercise | September 26, 2023 | Volume: 55 | Issue: 9S | Pages: 946-946

10.1249/01.mss.0000988644.46720.56 Get It